Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
14 Leser
Artikel bewerten:
(0)

Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences

BOCA RATON, Fla., Aug. 23 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals today announced that Dr. Leslie Hudson, interim president and chief executive officer will participate in the Thomas Weisel Partners Healthcare Conference, to be held Sept. 5-7, 2007 at The Four Seasons Hotel in Boston. Dr. Hudson's presentation at the conference is scheduled for Thursday, Sept. 6 at 2:05 p.m. EDT. Dr. Hudson is also scheduled to participate in the Bear Stearns Healthcare Conference, to be held Sept. 10-11, 2007 at The Grand Hyatt Hotel in New York, where he is slated to present on Tuesday, Sept. 11 at 2:30 p.m. EDT.

At both conferences, Dr. Hudson will present a company overview including a review of Nabi's corporate strategy and an update of its clinical development programs. Webcasts of these presentations and webcast information can be accessed on the company's "Events and Webcasts" page at http://www.nabi.com/.

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop and, in certain areas, market products that target serious medical conditions in the areas of hepatitis and transplants, gram positive bacterial infections and nicotine addiction. We are a vertically integrated company with sales of antibodies and other biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a pipeline of products in various stages of development, state-of-the-art manufacturing capability and a cash position that will allow us to advance our near-term pipeline products. The company operates through two strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi Biologics has responsibility for the company's protein and immunological products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine) development programs. For a complete list of pipeline products, please go to: http://www.nabi.com/pipeline/index.php. The company is headquartered in Boca Raton, Florida. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com/.

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.